SAN DIEGO--(BUSINESS WIRE)--Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will introduce its recently formed Cedar Therapeutics Inc. spin-out company at the Frost and Sullivan Venture Connections 2007 Executive Symposium on March 14, 2007. Cedar Therapeutics was formed to develop novel, proprietary, and superior formulations for certain drugs recently or soon-to-be off-patent addressing a current total market in excess of $11 Billion and eligible for FDA 505(b)2 accelerated regulatory treatment using Aegis’ proprietary Intravail® and ProTek® advanced proprietary drug delivery and formulation technologies.
